- Home
- AMLX vs SLRC Comparison
AMLX vs SLRC Comparison
Compare AMLX & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- SLRC
- Stock Information
- Founded
- AMLX 2014
- SLRC 2007
- Country
- AMLX United States
- SLRC United States
- Employees
- AMLX N/A
- SLRC N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- SLRC Finance/Investors Services
- Sector
- AMLX Health Care
- SLRC Finance
- Exchange
- AMLX Nasdaq
- SLRC Nasdaq
- Market Cap
- AMLX 749.9M
- SLRC 889.2M
- IPO Year
- AMLX 2022
- SLRC 2010
- Fundamental
- Price
- AMLX $10.20
- SLRC $16.70
- Analyst Decision
- AMLX Strong Buy
- SLRC Hold
- Analyst Count
- AMLX 7
- SLRC 6
- Target Price
- AMLX $12.29
- SLRC $16.13
- AVG Volume (30 Days)
- AMLX 1.3M
- SLRC 142.9K
- Earning Date
- AMLX 08-07-2025
- SLRC 11-05-2025
- Dividend Yield
- AMLX N/A
- SLRC 9.83%
- EPS Growth
- AMLX N/A
- SLRC N/A
- EPS
- AMLX N/A
- SLRC 1.63
- Revenue
- AMLX N/A
- SLRC $222,445,000.00
- Revenue This Year
- AMLX N/A
- SLRC N/A
- Revenue Next Year
- AMLX N/A
- SLRC $0.38
- P/E Ratio
- AMLX N/A
- SLRC $10.25
- Revenue Growth
- AMLX N/A
- SLRC N/A
- 52 Week Low
- AMLX $2.09
- SLRC $13.64
- 52 Week High
- AMLX $10.20
- SLRC $17.94
- Technical
- Relative Strength Index (RSI)
- AMLX 69.71
- SLRC 59.53
- Support Level
- AMLX $9.15
- SLRC $16.52
- Resistance Level
- AMLX $10.06
- SLRC $16.69
- Average True Range (ATR)
- AMLX 0.54
- SLRC 0.18
- MACD
- AMLX 0.12
- SLRC 0.03
- Stochastic Oscillator
- AMLX 98.53
- SLRC 90.74
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.